In this study, we identified the inhibitive roles of TUSC7 in lung cancer progression, and after acquiring the Erlotinib resistant cells, gene panel was used for massive assessing of the dysregulated non-coding RNAs. Here, TUSC7 is linked to lung carcinoma.